Sansure Biotech Inc. Class A

As of June 30, 2026, Sansure Biotech Inc. Class A carries a market capitalization of 8.34B, placing it among publicly traded companies globally. Its enterprise value stands at 6.13B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Sansure Biotech Inc. Class A's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Sansure Biotech Inc. Class A has 579.39M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Sansure Biotech Inc. Class A maintains a current ratio of 4.67, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Sansure Biotech Inc. Class A recorded 17.94M in income tax expense.

As of the close on October 22, 2026, Sansure Biotech Inc. Class A's stock has declined approximately 29.25% over the past 52 weeks. The 50-day moving average sits at 16.02, while the 200-day moving average is 17.16.

As of June 30, 2026, Sansure Biotech Inc. Class A holds 3.82B in cash and equivalents against 1.53B in total debt, resulting in a net debt position of -2.30B. Total book value stands at 6.99B, with working capital of 3.98B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Sansure Biotech Inc. Class A paid dividends of 0.30 per share.

Sansure Biotech Inc. Class A's most recent stock split took place on June 1, 2022 with a 25:37 split ratio.